Novartis Ag

Other

Catherine LeBlanc

David Andrew Sandham

Kamlesh Jagdis Bala

Nikolaus Johannes Stiefl

Brian Cox

Lyndon Nigel Brown

Ian Bruce

Clive McCarthy

Simon James Watson

Graham Charles Bloomfield

Robert Alexander Pulz

Katharine Louise Turner

Urs Baettig

Peter Hunt

Steven John Charlton

Louise Clare Kirman

Duncan Shaw

Judy Fox Hayler

Stephen Carl McKeown

Claire Adcock

Mrinalini Sachin Oza

Maude Nadine Pierrette Pipet

Robin Alec Fairhurst

Benoit Hornsperger

Bernard Cuenoud

Sven Weiler

Darren Mark Le Grand

Katrin Spiegel

Lewis Whitehead

Thomas Hugo Keller

Vikki Furminger

Dimitrios Lizos

Sarah Lewis

Nicola Press

Cathy Ritchie

Peter Finan

Lena Shukla

Harinder Pal Singh

Jake Axford

Gaynor Elizabeth Woodward

Lewis Whithead

Nicola Elaine Press

The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples. 

Substituted pyrido[2,3-B]pyrazines as IP receptor agonists

Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist

There are provided according to the invention compounds of formula (I), in free or salt form, wherein R, R, R, R, R, R, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals. 

Organic compounds

Pyrrolopyridine derivatives and their use as CRTH2 antagonists

Compounds of formula (I) in free or salt or solvate form, where T, T, and Thave the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. 

There are provided according to the invention compounds of formula (I) in free ors salt form, wherein R, R, R, R, R, A, D, X, W, m and n are as described in the specification, process for preparing them, and their use as pharmaceuticals.

Pyrrolopyridine compounds and their use in treating disease

Compounds of formula I: in free or salt or solvate form, where R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis. 

Compounds of formula I in free or salt or solvate form, where T, T, X, R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Compounds of formula I in free or salt form, wherein R, R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating diseases mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

5-phenylthiazole derivatives and use as PI3 kinase inhibitors

5-Phenylthiazole derivatives and their use as p13 kinase inhibitors

Compounds of formula (I) in free or salt or solvate form, where T, T, Rand Rhave the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. 

Pyrimidine derivatives as alk-5 inhibitors

in free or salt form, wherein R, R, R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylin ositol 3 kinase enzymes (PI13) for treatment of inflammatory diseases

Compounds of formula (I) in free or pharmaceutically acceptable salt form, where R, R, R, R, R, R, R, m, n, w, X, and Y have the meanings as indicated in the specification, are useful for treating conditions mediated by the CRThreceptor, especially inflammatory or obstructive airways diseases.

Organic compounds for the treatment of inflammatory or allergic conditions

There are provided according to the invention compounds of formula (I), in free or salt form, wherein R1, R2, R3, R 4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.

Pyrrolopyridine derivatives and their use as Crth2 antagonists

Growing community of inventors

Horsham, United Kingdom

Catherine LeBlanc